Drug Research
Community verified biological network models show promise for toxicology and drug discovery
A new set of community-produced biological network models has been shown to allow a deeper understanding of the mechanisms underlying a range of diseases. The models, of which earlier versions have been described in detail in...
Drug Research
Stem Cells May Speed Up Screening of Drugs for Rare Cancers
Researchers at the Johns Hopkins Kimmel Cancer Center say they have developed a system that uses transformed human stem cells to speed up screening of existing drugs that might work against rare brain and other cancers. ...
Drug Research
Sun Pharma rolls out first ready to administer anti cancer drug in six European countries
Sun Pharma, India's largest drug company has rolled out InfuSMART the first ever ready to administer version of anti cancer drug gemcitabine in six countries of Europe including Netherlands, UK, Spain, Germany, Italy and France. The...
Articles
The Anti-Counterfeit Drug Issue; It’s Real
Legislation is being put into place, but it is still essential that we all play a participative role in the continued fight to protect the patients that rely on our product.
Introduction
The issue of counterfeit pharmaceutical product is growing...
Articles
Fighting Cancer with targeted Drugs
“Diagnosis cancer” – this is a life-changing moment for many people. After cardiovascular diseases, cancer remains the next most common cause of death worldwide. In 2012, around 8.2 million people died as a result of cancer. According to the...
Drug Research
Takeda Pharmaceutical Company Licenses Global Rights to Theravance Biopharma’s TD-8954
Takeda and Theravance Biopharma, Inc. announced that the companies have entered into a global license, development and commercialization agreement for TD-8954, a selective 5-HT4 receptor agonist being investigated for potential use in the treatment of gastrointestinal motility disorders, including...
Drug Research
GSKs Bexsero achieves primary and secondary endpoints with reduced 3-dose schedule in safety and immunogenicity study in infants and children
GSK presented new data for its meningococcal group B vaccine, Bexsero®,1 comparing safety and immunogenicity with different dosing schedules in infants and young children, at the annual meeting of the European Society for Paediatric Infectious Diseases (ESPID). ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
